CA1340846E - Expression, dans des cellules eucaryotes, d'analogues de facteurs de croissance derives de plaquettes biologiquement actives - Google Patents

Expression, dans des cellules eucaryotes, d'analogues de facteurs de croissance derives de plaquettes biologiquement actives

Info

Publication number: CA1340846E
Authority: CA; Canada
Prior art keywords: pdgf; protein; polypeptide; dna; chain
Prior art date: 1984-10-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA 617115

Other languages

English (en)

Inventor

Mark Joseph Murray

James Darrel Kelly

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Zymogenetics Inc

Original Assignee

Zymogenetics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-10-12

Filing date

1999-06-11

Publication date

1999-12-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45478613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1340846(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1984-10-12 Priority claimed from US06/660,496 external-priority patent/US4769328A/en

1985-02-25 Priority to US06/705,175 priority Critical patent/US4801542A/en

1985-10-07 Priority to CA000492370A priority patent/CA1340212C/fr

1985-10-10 Priority to DE1999175042 priority patent/DE19975042I2/de

1985-10-10 Priority to EP85112852A priority patent/EP0177957B2/fr

1985-10-10 Priority to DE3588218T priority patent/DE3588218T2/de

1985-10-10 Priority to DE199191121387T priority patent/DE487116T1/de

1985-10-10 Priority to AU48454/85A priority patent/AU4845485A/en

1985-10-10 Priority to DE3586960T priority patent/DE3586960T3/de

1985-10-10 Priority to AT85112852T priority patent/ATE84312T1/de

1985-10-10 Priority to AT91121387T priority patent/ATE188255T1/de

1985-10-11 Priority to JP60226637A priority patent/JP2837407B2/ja

1990-05-10 Priority to AU54885/90A priority patent/AU638010B2/en

1997-10-16 Priority to JP28366397A priority patent/JP3145968B2/ja

1999-05-28 Priority to NL990016C priority patent/NL990016I2/nl

1999-06-11 Priority to CA 617115 priority patent/CA1340846E/fr

1999-06-11 Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc

1999-06-25 Priority to LU90408C priority patent/LU90408I2/fr

1999-12-07 Publication of CA1340846E publication Critical patent/CA1340846E/fr

1999-12-07 Application granted granted Critical

2005-10-07 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000014509 gene expression Effects 0.000 title claims abstract description 46
108010038512 Platelet-Derived Growth Factor Proteins 0.000 title description 95
102000010780 Platelet-Derived Growth Factor Human genes 0.000 title description 94
108090000623 proteins and genes Proteins 0.000 claims abstract description 128
210000004027 cell Anatomy 0.000 claims abstract description 121
108020004414 DNA Proteins 0.000 claims abstract description 75
102000004169 proteins and genes Human genes 0.000 claims abstract description 71
108700021652 sis Genes Proteins 0.000 claims abstract description 44
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 40
229920001184 polypeptide Polymers 0.000 claims abstract description 38
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 38
108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 36
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 29
241000714205 Woolly monkey sarcoma virus Species 0.000 claims abstract description 27
230000028327 secretion Effects 0.000 claims abstract description 25
230000004071 biological effect Effects 0.000 claims abstract description 22
230000012010 growth Effects 0.000 claims abstract description 15
230000002103 transcriptional effect Effects 0.000 claims abstract description 14
210000004962 mammalian cell Anatomy 0.000 claims abstract description 11
238000011144 upstream manufacturing Methods 0.000 claims abstract description 11
230000001737 promoting effect Effects 0.000 claims abstract description 8
239000013612 plasmid Substances 0.000 claims description 98
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 68
108700015934 Triose-phosphate isomerases Proteins 0.000 claims description 33
102000005924 Triose-Phosphate Isomerase Human genes 0.000 claims description 32
238000000034 method Methods 0.000 claims description 31
239000002773 nucleotide Substances 0.000 claims description 28
150000001413 amino acids Chemical group 0.000 claims description 27
125000003729 nucleotide group Chemical group 0.000 claims description 27
239000000539 dimer Substances 0.000 claims description 12
210000005253 yeast cell Anatomy 0.000 claims description 9
238000011282 treatment Methods 0.000 claims description 7
238000000338 in vitro Methods 0.000 claims description 6
208000027418 Wounds and injury Diseases 0.000 claims description 5
230000006378 damage Effects 0.000 claims description 5
208000014674 injury Diseases 0.000 claims description 5
108010038049 Mating Factor Proteins 0.000 claims description 3
230000013011 mating Effects 0.000 claims description 3
230000010076 replication Effects 0.000 claims description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
125000002228 disulfide group Chemical group 0.000 claims description 2
SKEFKEOTNIPLCQ-LWIQTABASA-N mating hormone Chemical compound C([C@@H](C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCS(C)=O)C(=O)NC(CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CN=CN1 SKEFKEOTNIPLCQ-LWIQTABASA-N 0.000 claims description 2
230000003612 virological effect Effects 0.000 claims 8
239000000710 homodimer Substances 0.000 claims 5
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 3
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
239000004473 Threonine Substances 0.000 claims 1
230000002297 mitogenic effect Effects 0.000 abstract description 24
230000003248 secreting effect Effects 0.000 abstract description 16
239000002299 complementary DNA Substances 0.000 abstract description 9
239000012634 fragment Substances 0.000 description 83
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 59
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
238000010276 construction Methods 0.000 description 27
239000000047 product Substances 0.000 description 26
101000845167 Woolly monkey sarcoma virus PDGF-related-transforming protein sis Proteins 0.000 description 19
239000002609 medium Substances 0.000 description 19
239000013598 vector Substances 0.000 description 19
239000000203 mixture Substances 0.000 description 18
239000000499 gel Substances 0.000 description 17
238000003556 assay Methods 0.000 description 14
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 13
239000000463 material Substances 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
108020004705 Codon Proteins 0.000 description 12
239000000872 buffer Substances 0.000 description 12
230000029087 digestion Effects 0.000 description 12
239000011543 agarose gel Substances 0.000 description 11
239000001963 growth medium Substances 0.000 description 11
229960000723 ampicillin Drugs 0.000 description 10
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
230000000694 effects Effects 0.000 description 10
239000013604 expression vector Substances 0.000 description 10
102000004594 DNA Polymerase I Human genes 0.000 description 9
238000013518 transcription Methods 0.000 description 9
230000035897 transcription Effects 0.000 description 9
229920000936 Agarose Polymers 0.000 description 8
108010017826 DNA Polymerase I Proteins 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
238000000605 extraction Methods 0.000 description 8
108020004999 messenger RNA Proteins 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
230000003362 replicative effect Effects 0.000 description 8
102000012410 DNA Ligases Human genes 0.000 description 7
108010061982 DNA Ligases Proteins 0.000 description 7
241000588724 Escherichia coli Species 0.000 description 7
108091034117 Oligonucleotide Proteins 0.000 description 7
230000002209 hydrophobic effect Effects 0.000 description 7
230000037361 pathway Effects 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
238000011160 research Methods 0.000 description 7
230000014616 translation Effects 0.000 description 7
108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
108700007698 Genetic Terminator Regions Proteins 0.000 description 6
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
238000012217 deletion Methods 0.000 description 6
230000037430 deletion Effects 0.000 description 6
238000001962 electrophoresis Methods 0.000 description 6
230000004927 fusion Effects 0.000 description 6
238000001556 precipitation Methods 0.000 description 6
230000008569 process Effects 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
241000894007 species Species 0.000 description 6
238000012360 testing method Methods 0.000 description 6
238000013519 translation Methods 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
241000206602 Eukaryota Species 0.000 description 5
101710112083 Para-Rep C1 Proteins 0.000 description 5
102100022881 Rab proteins geranylgeranyltransferase component A 1 Human genes 0.000 description 5
101710119887 Trans-acting factor B Proteins 0.000 description 5
238000000246 agarose gel electrophoresis Methods 0.000 description 5
229940098773 bovine serum albumin Drugs 0.000 description 5
239000012141 concentrate Substances 0.000 description 5
238000009396 hybridization Methods 0.000 description 5
238000003780 insertion Methods 0.000 description 5
230000037431 insertion Effects 0.000 description 5
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
102000002260 Alkaline Phosphatase Human genes 0.000 description 4
108020004774 Alkaline Phosphatase Proteins 0.000 description 4
241001131785 Escherichia coli HB101 Species 0.000 description 4
241001646716 Escherichia coli K-12 Species 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
101000708578 Milk vetch dwarf virus (isolate N) Para-Rep C3 Proteins 0.000 description 4
108091008606 PDGF receptors Proteins 0.000 description 4
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 4
244000309466 calf Species 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
210000002950 fibroblast Anatomy 0.000 description 4
239000008103 glucose Substances 0.000 description 4
238000012545 processing Methods 0.000 description 4
238000000746 purification Methods 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
210000000329 smooth muscle myocyte Anatomy 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
201000001320 Atherosclerosis Diseases 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
230000006820 DNA synthesis Effects 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241001524679 Escherichia virus M13 Species 0.000 description 3
101150007280 LEU2 gene Proteins 0.000 description 3
101710084218 Master replication protein Proteins 0.000 description 3
101150014925 POT1 gene Proteins 0.000 description 3
101710112078 Para-Rep C2 Proteins 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
102100022880 Rab proteins geranylgeranyltransferase component A 2 Human genes 0.000 description 3
241000235346 Schizosaccharomyces Species 0.000 description 3
239000012507 Sephadex™ Substances 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
101710119961 Trans-acting factor C Proteins 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
239000000306 component Substances 0.000 description 3
238000005520 cutting process Methods 0.000 description 3
230000002950 deficient Effects 0.000 description 3
-1 e.g. Proteins 0.000 description 3
229910001629 magnesium chloride Inorganic materials 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
244000005700 microbiome Species 0.000 description 3
239000003226 mitogen Substances 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
239000008188 pellet Substances 0.000 description 3
230000008488 polyadenylation Effects 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
230000007017 scission Effects 0.000 description 3
239000007858 starting material Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
230000002311 subsequent effect Effects 0.000 description 3
230000005030 transcription termination Effects 0.000 description 3
230000009466 transformation Effects 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 2
101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
238000001712 DNA sequencing Methods 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
230000005526 G1 to G0 transition Effects 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
108010037217 Oncogene Proteins v-sis Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
229920005654 Sephadex Polymers 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
101150033985 TPI gene Proteins 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
241001672648 Vieira Species 0.000 description 2
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 2
101100371145 Woolly monkey sarcoma virus V-SIS gene Proteins 0.000 description 2
ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 2
239000011149 active material Substances 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
230000032823 cell division Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
239000005547 deoxyribonucleotide Substances 0.000 description 2
125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
238000011161 development Methods 0.000 description 2
238000009585 enzyme analysis Methods 0.000 description 2
238000011049 filling Methods 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
230000002414 glycolytic effect Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
230000003902 lesion Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000008747 mitogenic response Effects 0.000 description 2
230000011278 mitosis Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
239000012071 phase Substances 0.000 description 2
238000007747 plating Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
238000010405 reoxidation reaction Methods 0.000 description 2
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 description 1
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
101710187578 Alcohol dehydrogenase 1 Proteins 0.000 description 1
102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010023063 Bacto-peptone Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000283707 Capra Species 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
101100102100 Drosophila melanogaster uri gene Proteins 0.000 description 1
206010014476 Elevated cholesterol Diseases 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
241000257303 Hymenoptera Species 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
102000004195 Isomerases Human genes 0.000 description 1
108090000769 Isomerases Proteins 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
241001314546 Microtis <orchid> Species 0.000 description 1
208000008636 Neoplastic Processes Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
101800001386 Peptide II Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
102000040739 Secretory proteins Human genes 0.000 description 1
108091058545 Secretory proteins Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
108091061763 Triple-stranded DNA Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
239000012491 analyte Substances 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000036523 atherogenesis Effects 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
239000012504 chromatography matrix Substances 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000009795 derivation Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
201000010099 disease Diseases 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
238000012224 gene deletion Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
230000000260 hypercholesteremic effect Effects 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000003999 initiator Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
230000007775 late Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000031700 light absorption Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000005541 medical transmission Effects 0.000 description 1
230000005499 meniscus Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
239000013642 negative control Substances 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
229940099990 ogen Drugs 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000027086 plasmid maintenance Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000001566 pro-viral effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
101150003680 rep-1 gene Proteins 0.000 description 1
230000008458 response to injury Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000011537 solubilization buffer Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000012085 test solution Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000000844 transformation Methods 0.000 description 1
150000003641 trioses Chemical class 0.000 description 1
XREXPQGDOPQPAH-QKUPJAQQSA-K trisodium;[(z)-18-[1,3-bis[[(z)-12-sulfonatooxyoctadec-9-enoyl]oxy]propan-2-yloxy]-18-oxooctadec-9-en-7-yl] sulfate Chemical compound [Na+].[Na+].[Na+].CCCCCCC(OS([O-])(=O)=O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O)COC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O XREXPQGDOPQPAH-QKUPJAQQSA-K 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000037314 wound repair Effects 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
- C12N2740/11022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/22—Viral peptide or viral protein
- Y10S930/221—Retrovirus related, or human immunodeficiency virus related, or simian immunodeficiency virus related

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Mycology (AREA)
Virology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Toxicology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Diaphragms For Electromechanical Transducers (AREA)
Dry Formation Of Fiberboard And The Like (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA 617115 1984-10-12 1999-06-11 Expression, dans des cellules eucaryotes, d'analogues de facteurs de croissance derives de plaquettes biologiquement actives Expired - Lifetime CA1340846E (fr)

Priority Applications (16)

Application Number	Priority Date	Filing Date	Title
US06/705,175 US4801542A (en)	1984-10-12	1985-02-25	Expression of biologically active PDGF analogs in eucaryotic cells
CA000492370A CA1340212C (fr)	1984-10-12	1985-10-07	Expression, dans des cellules eucaryotes, d'analogues de facteurs de croissance derives de plaquettes biologiquement actives
AT85112852T ATE84312T1 (de)	1984-10-12	1985-10-10	Expression, in eukaryotischen zellen, von biologisch aktiven analoga eines wachstumsfaktors, abstammend von blutplaettchen.
EP85112852A EP0177957B2 (fr)	1984-10-12	1985-10-10	Expression, dans des cellules de levure, d'analogues biologiquement actifs d'un facteur de croissance provenant de plaquettes sanguines
DE3588218T DE3588218T2 (de)	1984-10-12	1985-10-10	Von Blutplättchen abstammende biologisch aktive Analoga eines Wachstumsfaktors in eukaryotischen Zellen
DE199191121387T DE487116T1 (de)	1984-10-12	1985-10-10	Von blutplaettchen abstammende biologisch aktive analoga eines wachstumsfaktors in eukaryotischen zellen.
AU48454/85A AU4845485A (en)	1984-10-12	1985-10-10	Expression of human platelet derived growth factor (pgdf) analogs
DE3586960T DE3586960T3 (de)	1984-10-12	1985-10-10	Expression in Hefezellen, von biologisch aktiven Analoga eines Wachstumsfaktors, abstammend von Blutplättchen
DE1999175042 DE19975042I2 (de)	1984-10-12	1985-10-10	Expression in Hefezellen, von biologisch aktiven Analoga eines Wachstumsfaktors, abstammend von Blutplättchen.
AT91121387T ATE188255T1 (de)	1984-10-12	1985-10-10	Von blutplättchen abstammende biologisch aktive analoga eines wachstumsfaktors in eukaryotischen zellen
JP60226637A JP2837407B2 (ja)	1984-10-12	1985-10-11	生物学的に活性なｐｄｇｆ類似因子の真核生物細胞内での発現
AU54885/90A AU638010B2 (en)	1984-10-12	1990-05-10	Expression of biologically active platelet derived growth factor analogs in eucaryotic cells
JP28366397A JP3145968B2 (ja)	1984-10-12	1997-10-16	生物学的に活性なｐｄｇｆ類似因子の真核生物細胞内での発現
NL990016C NL990016I2 (nl)	1984-10-12	1999-05-28	Expressie van biologisch actieve analogen van uit bloedplaatjes afgeleide groeifactor in eukaryotische cellen.
CA 617115 CA1340846E (fr)	1984-10-12	1999-06-11	Expression, dans des cellules eucaryotes, d'analogues de facteurs de croissance derives de plaquettes biologiquement actives
LU90408C LU90408I2 (fr)	1984-10-12	1999-06-25	Regranex-becaplermin

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US660,496		1984-10-12
US06/660,496 US4769328A (en)	1984-10-12	1984-10-12	Expression of biologically active PDGF analogs in yeast
US06/705,175 US4801542A (en)	1984-10-12	1985-02-25	Expression of biologically active PDGF analogs in eucaryotic cells
US705,175		1985-02-25
CA000492370A CA1340212C (fr)	1984-10-12	1985-10-07	Expression, dans des cellules eucaryotes, d'analogues de facteurs de croissance derives de plaquettes biologiquement actives
CA 617115 CA1340846E (fr)	1984-10-12	1999-06-11	Expression, dans des cellules eucaryotes, d'analogues de facteurs de croissance derives de plaquettes biologiquement actives

Publications (1)

Publication Number	Publication Date
CA1340846E true CA1340846E (fr)	1999-12-07

Family

ID=45478613

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CA000492370A Expired - Lifetime CA1340212C (fr)	1984-10-12	1985-10-07	Expression, dans des cellules eucaryotes, d'analogues de facteurs de croissance derives de plaquettes biologiquement actives
CA 617115 Expired - Lifetime CA1340846E (fr)	1984-10-12	1999-06-11	Expression, dans des cellules eucaryotes, d'analogues de facteurs de croissance derives de plaquettes biologiquement actives

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CA000492370A Expired - Lifetime CA1340212C (fr)	1984-10-12	1985-10-07	Expression, dans des cellules eucaryotes, d'analogues de facteurs de croissance derives de plaquettes biologiquement actives

Country Status (9)

Country	Link
US (1)	US4801542A (fr)
EP (1)	EP0177957B2 (fr)
JP (2)	JP2837407B2 (fr)
AT (2)	ATE84312T1 (fr)
AU (2)	AU4845485A (fr)
CA (2)	CA1340212C (fr)
DE (4)	DE3586960T3 (fr)
LU (1)	LU90408I2 (fr)
NL (1)	NL990016I2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10071182B2 (en)	2014-10-14	2018-09-11	Samuel E. Lynch	Methods for treating wounds

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0259632B1 (fr) *	1986-08-13	1995-12-13	Zymogenetics, Inc.	Expression d'analogues de PDGF biologiquement actifs dans des cellules eucaryotiques
US5474982A (en) *	1986-08-13	1995-12-12	Zymogenetics, Inc.	PDGF analogs and methods of use
US5019559A (en) *	1986-11-14	1991-05-28	President And Fellows Of Harvard College	Wound healing using PDGF and IGF-II
AU624789B2 (en)	1987-02-19	1992-06-25	Amgen, Inc.	Purified platelet-derived growth factor and methods for purification thereof
DE3855504T2 (de) *	1987-04-22	1997-01-23	Chiron Corp	Rekombinante Herstellung von A-Ketten-Polypeptiden von PDGF
US6939849B1 (en)	1987-04-22	2005-09-06	Chiron Corporation	Recombinant PDGF A-chain homodimers and methods of use
US5219759A (en) *	1987-04-22	1993-06-15	Chiron Corporation	Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors
US5094941A (en) *	1987-12-31	1992-03-10	Zymogenetics, Inc.	Monoclonal antibodies to PDGF
US5759815A (en) *	1988-02-11	1998-06-02	Creative Biomolecules, Inc.	Production of platelet derived growth factor (PDGF) an muteins thereof
EP0422125B1 (fr) *	1988-06-30	1996-10-23	Cor Therapeutics, Inc.	Peptides bloquant des plaquettes
US5037743A (en) *	1988-08-05	1991-08-06	Zymogenetics, Inc.	BAR1 secretion signal
DE3900770A1 (de) *	1989-01-12	1990-07-26	Juergen Prof Dr Hoppe	Verfahren zur herstellung von pdgf-a und pdgf-aa
US6899882B1 (en)	1989-03-24	2005-05-31	The Regents Of The University Of California	Endothelial cell growth factor methods of isolation and expression
US5686410A (en) *	1989-07-20	1997-11-11	Novartis Ag	Polypeptide derivatives
US5219739A (en) *	1989-07-27	1993-06-15	Scios Nova Inc.	DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5272064A (en) *	1989-12-19	1993-12-21	Amgen Inc.	DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US6172039B1 (en)	1990-04-16	2001-01-09	Apex Bioscience, Inc.	Expression of recombinant hemoglobin and hemoglobin variants in yeast
AU8294991A (en) *	1990-07-23	1992-02-18	Zymogenetics Inc.	Protease resistant pdgf and methods of use
US5886141A (en) *	1990-10-26	1999-03-23	Takeda Chemical Industries, Ltd.	Smooth muscle mitogen peptides and DNA coding therefor
GB9101645D0 (en) *	1991-01-25	1991-03-06	British Bio Technology	Compounds
ES2099304T3 (es) *	1992-02-10	1997-05-16	Takeda Chemical Industries Ltd	Mitogeno de la musculatura lisa y adn que lo codifica.
ES2293137T3 (es)	1995-10-11	2008-03-16	Novartis Vaccines And Diagnostics, Inc.	Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
WO1998026080A1 (fr) *	1996-12-13	1998-06-18	Chiron Corporation	Procedes permettant d'exprimer des proteines heterologues dans la levure
EP1025212B1 (fr)	1997-10-14	2007-09-26	Darwin Molecular Corporation	Mutants et proteines de fusion de thymidine kinase presentant des activites de thymidine kinase et de guanylate kinase
US6194169B1 (en) *	1998-06-04	2001-02-27	The University Of Kentucky Research Foundation	Enhanced expression of human platelet-derived growth factor in Pichia pastoris
US20040009535A1 (en)	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
JP4813660B2 (ja)	1998-11-27	2011-11-09	ダーウィンディスカバリーリミテッド	骨鉱化作用を増加するための組成物および方法
US7063850B1 (en)	1998-12-22	2006-06-20	University Of Tennessee Research Foundation	Protective antigen of group A Streptococci
US6358733B1 (en)	2000-05-19	2002-03-19	Apolife, Inc.	Expression of heterologous multi-domain proteins in yeast
ATE405586T1 (de)	2001-05-08	2008-09-15	Darwin Molecular Corp	Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
CA2463008A1 (fr) *	2001-10-26	2003-07-24	Id Biomedical Corporation Of Washington	Systeme d'expression de proteine efficace
ES2496493T3 (es)	2002-01-11	2014-09-19	Bioasis Technologies Inc.	Uso de p97 como sistema de administración de enzimas para la administración de enzimas lisosómicas terapéuticas
US20030139333A1 (en) *	2002-01-18	2003-07-24	Genetix Pharmaceuticals, Inc.	Methods and compositions for promoting angiogenesis
US20050048041A1 (en) *	2003-01-13	2005-03-03	Rao Mahendra S.	Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
WO2008005533A2 (fr) *	2006-07-06	2008-01-10	Aaron Thomas Tabor	Compositions et procédés de modification génétique de cellules ayant une fonction cosmétique pour l'amélioration de l'aspect cosmétique
AU2006351377A1 (en)	2006-11-30	2008-06-05	University Of British Columbia	Poxviridae treatment comprising TAP-1 and/or TAP-2 as a molecular adjuvant
US9132202B2 (en)	2009-07-17	2015-09-15	Aaron T. Tabor	Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
PT2717917T (pt)	2011-07-05	2016-07-27	Bioasis Technologies Inc	Conjugados de anticorpos p97
AU2012294673B2 (en)	2011-08-05	2015-11-26	Bioasis Technologies Inc.	p97 fragments with transfer activity
US9932565B2 (en)	2012-07-31	2018-04-03	Bioasis Technologies, Inc.	Dephosphorylated lysosomal storage disease proteins and methods of use thereof
EP2970433B1 (fr)	2013-03-13	2019-09-18	Bioasis Technologies Inc.	Fragments de p97 et leurs utilisations
EP2967078B1 (fr)	2013-03-14	2018-10-17	GenVivo, Inc.	Dosage diagnostique des thymidine kinases pour applications de thérapie génique
JP6603227B2 (ja)	2014-02-03	2019-11-06	バイオアシステクノロジーズインコーポレイテッド	Ｐ９７融合タンパク質
ES2762672T3 (es)	2014-02-19	2020-05-25	Bioasis Technologies Inc	Proteínas de fusión de P97-IDS
WO2015168521A2 (fr)	2014-05-01	2015-11-05	Bioasis Technologies, Inc.	Conjugués p97-polynucléotides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4350687A (en) *	1980-02-10	1982-09-21	Research Corporation	Platelet derived cell growth factor
AU600885B2 (en) *	1984-05-25	1990-08-30	Zymogenetics Inc.	Stable DNA constructs

1985
- 1985-02-25 US US06/705,175 patent/US4801542A/en not_active Expired - Lifetime
- 1985-10-07 CA CA000492370A patent/CA1340212C/fr not_active Expired - Lifetime
- 1985-10-10 EP EP85112852A patent/EP0177957B2/fr not_active Expired - Lifetime
- 1985-10-10 DE DE3586960T patent/DE3586960T3/de not_active Expired - Lifetime
- 1985-10-10 DE DE199191121387T patent/DE487116T1/de active Pending
- 1985-10-10 AT AT85112852T patent/ATE84312T1/de active
- 1985-10-10 AU AU48454/85A patent/AU4845485A/en not_active Abandoned
- 1985-10-10 AT AT91121387T patent/ATE188255T1/de not_active IP Right Cessation
- 1985-10-10 DE DE3588218T patent/DE3588218T2/de not_active Expired - Lifetime
- 1985-10-10 DE DE1999175042 patent/DE19975042I2/de active Active
- 1985-10-11 JP JP60226637A patent/JP2837407B2/ja not_active Expired - Lifetime
1990
- 1990-05-10 AU AU54885/90A patent/AU638010B2/en not_active Expired
1997
- 1997-10-16 JP JP28366397A patent/JP3145968B2/ja not_active Expired - Lifetime
1999
- 1999-05-28 NL NL990016C patent/NL990016I2/nl unknown
- 1999-06-11 CA CA 617115 patent/CA1340846E/fr not_active Expired - Lifetime
- 1999-06-25 LU LU90408C patent/LU90408I2/fr unknown

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10071182B2 (en)	2014-10-14	2018-09-11	Samuel E. Lynch	Methods for treating wounds

Also Published As

Publication number	Publication date
DE3586960T3 (de)	2005-01-20
EP0177957A3 (en)	1988-02-03
JP3145968B2 (ja)	2001-03-12
EP0177957A2 (fr)	1986-04-16
US4801542A (en)	1989-01-31
NL990016I2 (nl)	1999-11-01
JP2837407B2 (ja)	1998-12-16
JPS62278A (ja)	1987-01-06
DE3588218D1 (de)	2000-02-03
DE3586960D1 (fr)	1993-02-18
AU4845485A (en)	1986-04-17
AU638010B2 (en)	1993-06-17
DE487116T1 (de)	1992-10-15
CA1340212C (fr)	1998-12-15
ATE84312T1 (de)	1993-01-15
AU5488590A (en)	1991-01-31
EP0177957B2 (fr)	2004-08-25
DE19975042I2 (de)	2004-01-29
DE3588218T2 (de)	2000-05-18
EP0177957B1 (fr)	1993-01-07
DE3586960T2 (de)	1993-05-13
ATE188255T1 (de)	2000-01-15
JPH10117790A (ja)	1998-05-12
LU90408I2 (fr)	1999-08-25
NL990016I1 (nl)	1999-08-02

Legal Events

Date	Code	Title	Description
1999-12-07	NARE	Reissued
2016-02-16	MKEX	Expiry	Effective date: 20151215

Publication	Publication Date	Title
CA1340212C (fr)	1998-12-15	Expression, dans des cellules eucaryotes, d'analogues de facteurs de croissance derives de plaquettes biologiquement actives
US4769328A (en)	1988-09-06	Expression of biologically active PDGF analogs in yeast
US4845075A (en)	1989-07-04	Biologically active B-chain homodimers
US5045633A (en)	1991-09-03	Expression of biologically active PDGF analogs in eucaryotic cells
US4889919A (en)	1989-12-26	Biologically active PDGF derived A-chain homodimers
US5187263A (en)	1993-02-16	Expression of biologically active PDGE analogs in eucaryotic cells
US5516896A (en)	1996-05-14	Biologically active B-chain homodimers
Lang et al.	1985	Expression of a hemopoietic growth factor cDNA in a factor-dependent cell line results in autonomous growth and tumorigenicity
AU599572B2 (en)	1990-07-26	Lymphokine production and purification
US5094941A (en)	1992-03-10	Monoclonal antibodies to PDGF
EP0897987A2 (fr)	1999-02-24	Sécrétion de protéine humaine associée au peptide-signal de l' interferon gamma
EP0259632B1 (fr)	1995-12-13	Expression d'analogues de PDGF biologiquement actifs dans des cellules eucaryotiques
JPH04504064A (ja)	1992-07-23	新規血小板由来成長因子ｂ鎖類似体及びその均質製造方法
EP0164403B1 (fr)	1991-08-28	Vaccin du virus de la leucemie chez les felins
JPS6255088A (ja)	1987-03-10	組換えｄｎａ技術によるｂ型肝炎表面抗原
EP0487116B1 (fr)	1999-12-29	Analogues biologiquement actifs d'un facteur de croissance provenant de plaquettes sanguines dans des cellules eucaryotiques
US5498600A (en)	1996-03-12	Biologically active mosaic proteins
EP0139216B1 (fr)	1990-07-25	Antigène peptidique contre le virus de la leucémie de cellules T adultes
EP0162319B1 (fr)	1992-11-19	Procédé de ligation de gènes hétérogènes
JPS6112288A (ja)	1986-01-20	真核細胞の形質転換のための補助ｄｎａを含むベクタ−
Ko et al.	1984	Plasmid-directed synthesis of genuine adenovirus 2 early-region 1A and 1B proteins in Escherichia coli
AU641816B2 (en)	1993-09-30	Expression of biologically active PDGF analogs in eucaryotic cells
Méndez et al.	1991	Recombinant Yeast as a Production System
JPH01117780A (ja)	1989-05-10	組み換えワクチニアウイルス

CA1340846E - Expression, dans des cellules eucaryotes, d'analogues de facteurs de croissance derives de plaquettes biologiquement actives - Google Patents

Info

Links

Classifications

Landscapes

Priority Applications (16)

Applications Claiming Priority (6)

Publications (1)

Family

ID=45478613

Family Applications (2)

Family Applications Before (1)

Country Status (9)

Cited By (1)

Families Citing this family (45)

Family Cites Families (2)

Cited By (1)

Also Published As

Similar Documents

Legal Events